Equities

Coherus BioSciences Inc

Coherus BioSciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.15
  • Today's Change0.05 / 4.55%
  • Shares traded3.14m
  • 1 Year change-42.21%
  • Beta0.7626
Data delayed at least 15 minutes, as of Nov 21 2024 18:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform4
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Coherus Biosciences Inc have a median target of 7.00, with a high estimate of 23.00 and a low estimate of 1.50. The median estimate represents a 536.36% increase from the last price of 1.10.
High1,990.9%23.00
Med536.4%7.00
Low36.4%1.50

Earnings history & estimates in USD

On Nov 06, 2024, Coherus Biosciences Inc reported 3rd quarter 2024 losses of -0.01 per share. This result exceeded the -0.13 consensus loss of the 6 analysts covering the company and exceeded last year's 3rd quarter results by 96.30%.
The next earnings announcement is expected on Mar 11, 2025.
Average growth rate+16.97%
Coherus Biosciences Inc reported annual 2023 losses of -1.98 per share on Mar 13, 2024.
Average growth rate-30.66%
More ▼

Revenue history & estimates in USD

Coherus BioSciences, Inc. had 3rd quarter 2024 revenues of 70.77m. This bettered the 59.23m consensus of the 8 analysts covering the company. This was 118.20% above the prior year's 3rd quarter results.
Average growth rate+0.04%
Coherus BioSciences, Inc. had revenues for the full year 2023 of 257.24m. This was 21.89% above the prior year's results.
Average growth rate-2.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.